medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

# Sustained seroprevalence of anti SARS-CoV-2 total immunoglobulins in asymptomatic blood donors

M Carmen Martín [1]

M Isabel González [1]

Nuria Holgado [1]

Ana I Jimenez [1]

Nuria Ortega [1]

Isabel Page [1]

Alba Parrado[1]

María Pérez [1]

Lydia Blanco-Peris [1]

[1]Centro de Hemoterapia y Hemodonación de Castilla y León

**Running Title:** Seroprevalence of anti SARS-CoV-2 in asymptomatic blood donors

**Keywords:** total immunoglobulins, SARS-CoV-2, seroprevalence, blood donors

**Corresponding author:** M Carmen Martín; cmartinalo@saludcastillayleon.es; Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos, Valladolid, Spain

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

# Sustained seroprevalence of anti SARS-CoV-2 total immunoglobulins in asymptomatic blood donors


## Abstract

**Background:** Seroprevalence analysis of SARS-CoV-2 is one of the keys to accurately monitor pandemics and help the authorities make health decisions and adjust the current social interventions. The aim of this study was to determine retrospective seroprevalence evolution among blood donors along prepandemic months, and the first wave in Spain. A secondary objective was to determine whether age, blood group or haematological parameters are related to recent past infection.

**Material and Methods:** A total of 12719 donations SARS-CoV-2 from July 2019 to October 2020 were analysed. Donors were 60.9% males and their average age was 46+/-13. An automated chemiluminiscence double-antigen sandwich immunoassay for the in vitro semi quantitative detection of total antibodies to SARS-CoV-2 in human serum and plasma was performed.

**Results:** Seropositivity donation rate grew up from week 11 to week 21, reaching plateau by near 8% donations, sustained until week 43 when 2nd wave arose in our country. 6.7% individuals were positive by the end of 1st wave. No differences by sex age or blood group were found regarding antibodies. Lymphocyte were significantly higher in positive woman as compared to negative ones and haemoglobin were lower in positive men as compared to negative ones.

**Discussion:** Seroprevalence due to asymptomatic cases would be equivalent to that of general population. Sex and age would not affect COVID-19 susceptibility but its severity. Gender differences are present even in asymptomatic individuals: females are possibly protected by their relative lymphocytosis and neutropenia whereas males are would be weaker as seropositive men show a decrease of haematocrit and haemoglobin. Further studies are needed to confirm these gender differences not only in severe but as well in asymptomatic cases as they can help better understand COVID19 pathogenesis and prognosis.


## Introduction

SARS-CoV-2 infection curses asymptomatic or with just mild symptoms in a number of cases. This make it hard to calculate accurate infection or fatality rates and prevalence. These calculations are important for evaluating risks of COVID-19 disease, predicting the spread of the virus and managing health resources [1].

Most cases develop an effective immune response during infection, leading to viral eradication and the production of specific T cell responses and antibodies against SARS-CoV-2 that are usually detectable 10–21 days after infection.

Antibody assays are quite different: they either detect antibodies against different viral proteins (S1, S1/S2, RBD or NC) or different immunoglobulin classes: IgG, IgM, IgA or their combinations. To make it even messier, many factors can influence test performance, including cross-reactivity with other coronaviruses or platform (laboratory-based vs point-of-care, lateral flow). Chemiluminiscence assays have suitable performances regarding both sensibility and sensitivity,

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

even though those values have been estimated as testing populations with compatible symptoms and would be presumably lower when performing serosurveillance analysis on apparently healthy population. Chemiluminiscent immunoassays exhibit a significantly higher specificity score but a lower sensitivity, as compared to ELISA immunoassays. Moreover, immunoassays detecting IgG antibodies against SARS-CoV-2 N protein instead of S protein alone are more reliable, considering both specificity and sensitivity scores [2].

SARS-CoV-2 disease burden is suspected to be much larger than reported COVID-19 cases due to low detection rates, especially at the beginning of pandemics. Seroprevalence surveys are needed to monitor the pandemic, both before and after vaccination strategies. [3] Reported COVID-19 cases do not represent the full SARS-CoV-2 disease burden. Case reports are dependent on patients seeking health care, massive local screenings or regional tracking activities. Analysis of data from seroprevalence and serosurveillance is a common strategy for estimating underreporting and real disease burden. There are several features that should be taken into account, including time between infection and antibody development or antibody waning, which must be considered to understand seroprevalence surveys avoiding biases as. Any seroprevalence survey should be evaluated for selection bias. Serological surveys with a random sampling design of the general population are difficult to perform in a pandemic, but a random sampling design of the general population yields a seroprevalence estimate least likely to be affected by selection bias. Blood donors are a quite representative subset of general population aged 18-65.

Blood donor-based serosurveillance is a powerful and cost-effective strategy to monitor infectious diseases. There are quite a lot of infections for which routine donor screening is well known to be useful, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-lymphotrophic virus (HTLV), and West Nile virus (WNV) [1], babesiosis or Crimea-Congo fever. The use of blood donor samples means we're sampling mainly asymptomatic and recovered cases of COVID-19 (normal blood donation is allowed after 28 days following COVID-19 symptoms' resolution).

Heterogeneity of susceptibility and transmission is hard to evaluate but does exist[4]. A portion of the population is not susceptible to infection from the first pathogen contact. Some may have pre-existing immunity via cross-reactivity or particular host factors such as mucosal immunity or trained innate immunity protection (as it has been reported to be conferred by DTP or BCG vaccination [5]). There is as well a proportion of seronegative individuals that will develop immunity by T cell mediated responses but without exhibiting an antibody response [6].

Castilla y Leon, with a population of 2.299.598 inhabitants, has accumulated 221.816 confirmed cases (https://analisis.datosabiertos.jcyl.es/ ), with an overall case-fatality rate of 4.85 to date.

Our institution, Centro de Hemoterapia de Castilla y León keeps within its Biobank serum samples from every single donor along the last ten years, that makes up around 1 million sera together with their demographical data such as sex or age and laboratory parameters (blood counts, blood group, haemoglobin, etc…) . The Biobank of the Centro de Hemoterapia de Castilla y León is included in the National Registry of Biobanks (RD17 / 16/2011) with the number

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

B.0000264 and holds an ISO 9001: 2015 certification endorsing our granting of safety and traceability of any human biological sample we distribute, always behaving Spanish and European rules on human samples and data protection management.

The starting hypothesis is the existence of a certain number of asymptomatic carriers of the SARS-CoV-2 virus that would develop antibodies against the new coronavirus [6] (and subsequently contribute to herd immunity). There are recently described early cases in France [7], arising the question of whether the pathogen could have been circulating even before the official recording of the first cases in Spain by January 31st, 2020.

The main aim of this study is to detect serum antibodies to determine what percentage of the population has had contact with the virus at different times and has therefore developed antibodies against it. A secondary goal is to establish whether sex, age, blood group or haematological abnormalities are related to recent past infection. This epidemiological features would make it possible to optimize hospital management of COVID19 cases, make a good forecast of resources for possible future outbreaks, and would facilitate decisions in the social sphere by reliably knowing the percentage of immunized patients.

## MATERIALS AND METHODS

*Aim, design and setting of the study*

The aim of this study was to obtain, a reliable knowledge of asymptomatic COVID-19 cases and their immunological and haematological characteristics, seroprevalence, rate of positive donations and its temporal evolution along the first wave. So, a retrospective observational analysis was performed.

*Participants*

The study population comprised randomised samples from blood, plasma (excluding convalescent) and platelet donations from July 2019 to October 2020. A total of 12718 samples of 11444 donors over 18 years old were included.

*Data collection*

All haematological and demographical data were extracted from electronic medical records. The collection form included age, sex, blood group, and laboratory data.

*Laboratory data an analyses*

Major laboratory markers were extracted from medical records. Routine blood examinations included leukocyte (WBC), neutrophil, lymphocyte, platelet, monocyte, eosinophil and basophil counts (cells*10^3/µL) and their percentages. Serum biochemical tests recorded were immunoglobulins IgG, IgA and IgM (mg/dL). Haemoglobin (Hb), haematocrit (HCT) and corpuscular mean volume were analysed as well. An automated chemiluminiscence double-antigen sandwich immunoassay for the in vitro semi quantitative detection of total antibodies to SARS-CoV-2 in human serum and plasma was performed. Target antigen of the immunoassay is a recombinant nucleocapsid (N) protein. Elecsys® Anti-SARS-CoV-2 detects antibodies correlating with virus-neutralizing ones and is therefore useful to help characterize the immune reaction to SARS-CoV-2 [9,10]. Immunoassay was validated by testing of 6 pairs of samples (plasma EDTA and

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

serum) from diagnosed PCR-positive, symptomatic cases infected by mid-April, that were previously reported positive by the CMV, and checked to be as well positive for IgG (Chemiluminiscence, N protein, Abbott Alinity S) and IgA (ELISA, S protein, Euroimmunn) antiSARS-CoV-2 and another set of ten prepandemic samples therefore supposed to be negative. A 100% concordance was yielded by these validation assays. The cut-off was that recommended by manufacturer (OD>1 to report reactivity).

*Statistical analysis*

Demographic and clinical characteristics of patients were expressed as their mean/median and standard deviation (SD) for continuous variables and frequency distributions are reported for categorical variables. Age was analysed both as continuous and categorical variable; in the latter case was recoded into 4 groups: <30, 30-45, 45-60, 60-75 years old.

Kolmogorov-Smirnov test was performed on each continuous variable to contrast normality and only IgG and IgM followed normal distributions, therefore non-parametric Krusal-Wallis test was performed to compare laboratory values. To contrast the Ho of independence within categorical variables, Pearson's Chi-square and Fisher's exact test were carried out.

*Ethics approval*

This study was conducted according with national regulations, institutional policies and in the tenets of the Helsinki Declaration. This study was approved, with the Valladolid Health Area Drug Research Ethics Committee acting as the main committee, in a meeting held on June 11, 2020 with the reference number "BIO-2020-93".

*Availability of data and materials*

Data collected for the study, including fully anonymized participant data, are available to others. Data available include fully anonymized participant data and data dictionary. Related documents are available from the date of publications henceforth: study protocol, statistical analysis, and approval of Ethical Board. These documents are available from the date of publications henceforth at email address cmartinalo@saludcastillayleon.es. Data would be shared after approval of proposals by the Valladolid Este Ethical Committee.

*Abbreviations.*

Immunoglobulin G (IgG); immunoglobulin A (IgA); immunoglobulin M (IgM); polymerase chain reaction (PCR); standard deviation (SD); interquartile range (IQR); White blood cells (WBC), haemoglobin (Hb), haematocrit (HCT), mean corpuscular volume (MCV).

## Results

A total of 12718 donations (either whole blood, plasmapheresis or platelet apheresis) were tested for total anti SARS-CoV2 antibodies. Donors made up 11444, 60.91% males, aged 18-75, average 46+/-13, 45.8%A, 40.3% O,

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

10.56%B, 3.31%AB. 660 out of 9886 single donors were positive within weeks 11 to 43, that makes a seroprevalence of 6.73% at the end of the first wave.

Donations collected since 19/07/2019 (week -24) to 19/10/2020 (week 43) were analysed

Seropositivity rate grew up from week 11 to week 21, reaching a 7.8% plateau, with just subtle changes until week 43 when 2nd wave arose in our country. Plateau was reached by the last week of May 2020, 11 weeks after close lockdown in Spain, that begun in March, 15th and 17 weeks after 31/01, the date of the first declared case. As can be seen in Figure 1, a pronounced slope can be appreciated from then to plateau at week 22.

Three donations yielded positive results along 2019 (July, September and October) but none of them were positive when testing separately IgG, IgA or IgM. Their OD were 1.05, 1.08 and 5.46 respectively. 1142 donations from year 2019 were analysed.

No differences in anti SARS-CoV2 reactivity due to sex, age or blood group of donors were found (Table I)

Immunoglobulin levels didn't show any differences as comparing positive and negative donations but haemoglobin (14.9 vs 17.7 g/dL; $p<0.05$) and haematocrit (45.2% vs 44.4%) were both significantly lower in positive donations (Supplementary Table I). WBC were slightly lower (7.5 vs 7.2 cells*10^3/µL; $p<0.02$).

As splitting data by sex, the fact arose that lower haemoglobin (46.8% vs 45.9%; $p<0.05$) and haematocrit (15.5 vs 15.3 g/dL; $p<0.05$) were significantly different just in males and that positive females had significantly lower WBC (7.67 vs 7.25 cells*10^3/µL) and neutrophil numbers (4.53 vs 4.27 cells*10^3/µL) and percent, and conversely, a higher lymphocyte percent as a trend (31.7% vs 33.10%; $p<0.2$) with significantly lower count (2.39 vs 2.35 cells*10^3/µL $p<0.05$). A trend of lower platelet count in positive women was observed (261 vs 255 cells*10^3/µL; $p<0.02$) and monocyte (0.46 vs 0.44 cells*10^3/µL) and higher monocyte (0.4 vs 0.5 cells*10^3/µL). No other significant differences were found either in males, females or overall.

## Discussion

A seroprevalence around 6.73% (7.8% of donations) was reached and sustained in our region regarding 18-75 years old population without COVID-19 antecedents. This fact agrees with the seroprevalence study ENE-COVID19 promoted by the *Instituto Nacional the Epidemiología* [11], where is reported that a 7.2% of the participants in our region would have anti SARS-CoV2 IgG antibodies by the end of June. It is to notice that almost ¼ people in our region (25.51% according to National Institute of Statistics, INE 2020 data) is older than 65 and are necessarily underrepresented in this study as it comprises blood donors. That happens as well with population under 18 (under 4.5%).

The first case in Spain was reported on 31/01/2020, but 3 positive donations were found as testing samples collected along 2019. That could be meaningful in two opposite ways: one possible explanation would be cross reactivity to seasonal cold coronaviruses and the other would be that SARS-COV-2 would have been circulating at least since 2019 summer.

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Although the possibility of cross reactivity has been widely commented in mass media, little scientific literature can be found to date. It has been checked that long-term cross-reactive both T-cell and antibodies can be a correlate of protections against COVID-19 [8]. It will be therefore important to determine the magnitude and prevalence of this correlates to accurately determine the immunization status of populations, the so named herd immunity.

There are as well reports about SARS-CoV-2 circulating in Europe along 2019. Italy's Ministry of Health reported high levels of "unusual" strains of flu and pneumonia concentrated in the area around Milan and appearing in 17 of Italy's 20 regions [12]. Our three donors would be even earlier cases.

Conversely to clinical forms of COVID-19 [13] neither age nor sex have an influence on the probability to develop an asymptomatic infection. Another seroprevalence reports from european countries support this feature [14-18]. It may be therefore ascertained that age and sex do not have a role in SARSCoV-2 infection susceptibility, but only in their progression to severe forms.

Blood group has been reported elsewhere [6, 19, 20] to confere susceptibility or determine severity (most studies do not split these two concepts) to SARS-CoV2 infection. Relationship with susceptibility is not supported by our data. We excluded convalescent plasma donors, opposite to other studies, that focused into these donors [20].Perhaps blood group might be related only to clinical cases and therefore linked to severity but not related to asymptomatic infection. Another surface antigens such as HLA or KIR might be as well involved and should be studied.

Several blood count anomalies have been reported to be associated to SARS-CoV2 infection, notably lymphopenia and neutrophilia [21]. Conversely, our data reveal that asymptomatic positive women had a significant neutropenia and lymphocytosis as compared to negative ones. Perhaps this feature is a correlate of protection against clinical severity. Mortality in COVID-19 is associated to low haemoglobin [22]. In our series, haemoglobin and haematocrit were present just in positive males as compared to negative ones. A hampering in O2 transport due to hem- group [23] destruction has been reported to be responsible for that bad prognosis. It seems as if males were more labile to this damage after infection, being this effect visible even when no symptoms are present.

## Conclusions

We can conclude that seroprevalence due to asymptomatic cases is equivalent to that of general population. Sex and age would not affect COVID-19 susceptibility but its severity. Gender differences are present even in asymptomatic individuals: females are possibly protected by relative lymphocytosis and neutropenia whereas males are would be weaker as seropositive men show a decrease of haematocrit and haemoglobin. Further studies are needed to confirm these gender differences not only in severe but as well in asymptomatic cases as they can help better understand COVID19 pathogenesis and prognosis.

## Acknowledgements

The authors thank to all blood donors making this work possible by allowing research use of their samples by the Biobanco del Centro de Hemoterapia y

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Hemodonación de Castilla y León. They also thank the staff in charge of blood donation, and lab technicians for their efforts and Roche for its support.

**Funding and resources**

This work has been carried out provided free equipment and test reagents from Roche Diagnostics International Ltd.

**Authors' contributions**

LB and MCM conceived the idea for this study, designed the protocol, analysed the data and drafted the manuscript. IP, AJ and MIGF were in charge of laboratory data. All authors provided critical revisions and approved the final version of the manuscript.

**Disclosure of conflicts of interest**

Authors stated no conflicts of interest although M Carmen Martin will speak about this issue in a sponsored symposium of Roche Diagnostics International Ltd.

**References**

1. Busch MP, Stone M. Serosurveillance for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood Donor Populations. Clin Infect Dis. 2020;**72(2)**:254-256
2. Speletas M, Kyritsi MA, Vontas A, et al. Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients' Management. *Front Immunol*. 2020;**11**:609242
3. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. *JAMA Netw Open*. 2021;**4(1)**:e2033706
4. Friston K, Costello A, Pillay D. 'Dark matter', second waves and epidemiological modelling. *BMJ Glob Health*. 2020;**5(12)**:e003978
5. Netea MG, van der Meer JW, van Crevel R. BCG vaccination in health care providers and the protection against COVID-19. *J Clin Invest*. 2021;**131(2)**:e145545
6. Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibilia J, Candon S, Fafi-Kremer S. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. Emerg Infect Dis. 2021;**27**(1):113–21

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .


7. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. *Antiviral Res*. 2020;181:104880

8. Poonia B, Kottilil S. Immune Correlates of COVID-19 Control. *Front Immunol*. 2020;**11**:569611

9. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin Virol*. 2020;**129**:104480

10. Müller L, Ostermann PN, Walker A, et al. Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting [published online ahead of print, 2021 Feb 3]. *Eur J Clin Microbiol Infect Dis*. 2021;**1**-9

11. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. *BMJ*. 2020;**371**:m4509.

12. Murtas R, Decarli A, Russo AG. Trend of pneumonia diagnosis in emergency departments as a COVID-19 surveillance system: a time series study. BMJ Open. 2021;**11**(2):e044388.

13. Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. Immun Ageing. 2020;**17**:22

14. Dickson E, Palmateer NE, Murray J, et al. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. *Public Health*. 2021;**190**:132-134

15. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. *Lancet Glob Health*. 2020;**8**(11):e1390-e1398.

16. Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. *Euro Surveill*. 2020;25(31):2001369

17. Biggs HM, Harris JB, Breakwell L, et al. Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;**69**(29):965-970

18. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*. 2020;396(10247):313-319

19. Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO Blood Types and COVID-19: Spurious, Anecdotal, or Truly Important Relationships? A Reasoned Review of Available Data. *Viruses*. 2021;**13**(2):160

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

20. Muñiz-Diaz E, Llopis J, Parra R, et al. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. *Blood Transfus*. 2021;**19**(1):54-63

21. Agbuduwe C, Basu S. Haematological manifestations of COVID-19: From cytopenia to coagulopathy. *Eur J Haematol*. 2020;**105**(5):540-546

22. Goud PT, Bai D, Abu-Soud HM. A Multiple-Hit Hypothesis Involving Reactive Oxygen Species and Myeloperoxidase Explains Clinical Deterioration and Fatality in COVID-19. Int J Biol Sci. 2021 Jan 1;**17**(1):62-72

23. Dattilo M. The role of host defences in Covid 19 and treatments thereof. *Mol Med*. 2020;**26**(1):90

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

## Tables

| | Negative | | Positive | |
|---|---|---|---|---|
| | **n** | **%** | **n** | **%** |
| Female | 4531 | 38,1% | 164 | 40,3% |
| Male | 7375 | 61,9% | 243 | 59,7% |
| <30 | 3551 | 29,8% | 104 | 25,6% |
| 30 to 45 | 5036 | 42,3% | 180 | 44,2% |
| 45 to 60 | 1151 | 9,7% | 42 | 10,3% |
| 60 to 75 | 2168 | 18,2% | 81 | 19,9% |
| A | 5411 | 45,5% | 198 | 48,6% |
| AB | 423 | 3,6% | 16 | 3,9% |
| B | 919 | 7,7% | 22 | 5,4% |
| O | 5151 | 43,3% | 171 | 42,0% |

Table I. Sex, age range and blood group of positive/negative anti SARS-COV2 donations analysed

| | | n | mean | median | SD | IQR |
|---|---|---|---|---|---|---|
| Age | Negative | 11906 | 44.0 | 45.8 | 12.8 | 34.2-54.2 |
| | Positive | 407 | 44.2 | 46.5 | 13.0 | 32.8-54.8 |
| IgA | Negative | 194 | 236.9 | 223.5 | 101.3 | 163-292 |
| | Positive | 5 | 224.4 | 274.0 | 92.3 | 134-282 |
| IgG | Negative | 194 | 1065.4 | 1037.5 | 217.4 | 910-1185 |
| | Positive | 5 | 1123.8 | 1095.0 | 249.9 | 924-1229 |
| IgM | Negative | 194 | 113.3 | 100.5 | 64.8 | 69-138 |
| | Positive | 5 | 103.0 | 89.0 | 41.7 | 78-97 |
| WBC | Negative | 11219 | 7.5 | 7.2 | 1.8 | 6.16-8.5 |
| | Positive | 386 | 7.2 | 7.1 | 1.6 | 6.15-8.22 |
| Hb* | Negative | 11218 | 14.9 | 14.9 | 1.3 | 14-15.8 |
| | Positive | 386 | 14.7 | 14.7 | 1.2 | 13.8-15.4 |
| Hematocrite* | Negative | 11218 | 45.1 | 45.2 | 3.5 | 42.7-47.6 |
| | Positive | 386 | 44.5 | 44.4 | 3.5 | 42.3-46.6 |
| Platelets | Negative | 11217 | 247.9 | 243.0 | 54.3 | 211-280 |
| | Positive | 386 | 247.3 | 242.5 | 55.7 | 206-276 |
| Neutrophil count | Negative | 11217 | 4.4 | 4.3 | 1.4 | 3.44-5.19 |
| (t) | Positive | 386 | 4.3 | 4.2 | 1.2 | 3.34-5.03 |
| Neutrophil % | Negative | 11217 | 58.8 | 58.9 | 7.5 | 53.8-63.9 |

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

| | | | | | | |
|---|---|---|---|---|---|---|
| | Positive | 386 | 58.5 | 58.7 | 7.1 | 54.3-63.4 |
| Lymphocyte count | Negative | 11216 | 2.3 | 2.3 | 0.7 | 1.86-2.72 |
| | Positive | 386 | 2.3 | 2.2 | 0.6 | 1.89-2.64 |
| Lymphocyte % | Negative | 11216 | 31.7 | 31.5 | 6.9 | 27-36.2 |
| | Positive | 386 | 32.1 | 32.4 | 6.6 | 27.3-36.1 |
| Monocyte count | Negative | 11216 | 0.5 | 0.46 | 0.1 | 0.38-0.56 |
| | Positive | 386 | 0.5 | 0.46 | 0.1 | 0.37-0.54 |
| Monocyte % | Negative | 11216 | 6.5 | 6.4 | 1.5 | 5.5-7.4 |
| | Positive | 386 | 6.5 | 6.4 | 1.4 | 5.5-7.3 |
| Eosinophil count | Negative | 11217 | 0.2 | 0.2 | 0.1 | 0.09-0.23 |
| | Positive | 386 | 0.2 | 0.1 | 0.1 | 0.09-0.22 |
| Eosinophil % | Negative | 11217 | 2.5 | 2.1 | 1.8 | 1.3-3.2 |
| | Positive | 386 | 2.4 | 2.0 | 1.7 | 1.3-3.1 |
| Basophil count | Negative | 11217 | 0.0 | 0.0 | 0.0 | 0.02-0.04 |
| | Positive | 386 | 0.0 | 0.0 | 0.0 | 0.02-0.04 |
| Basophil % | Negative | 11217 | 0.5 | 0.5 | 0.2 | 0.3-0.6 |
| | Positive | 386 | 0.5 | 0.5 | 0.3 | 0.4-0.6 |

*p<0.001

(t)p<0.2

Supplementary Table I. Descriptive analysis of age, immunoglobulins (mg/dL), Hb(g/dL), MCV, hemogram counts (cells*10^3/µL) and percents, of reactive and non-reactive donations

| | | | n | mean | median | SD | IQR |
|---|---|---|---|---|---|---|---|
| Age | Female | Negative | 4531 | 42.0 | **43.50** | 13.3 | 30.3-53.3 |
| | | Positive | 164 | 42.1 | **45.39** | 13.6 | 28.6-53.1 |
| | Male | Negative | 7375 | 45.2 | **46.81** | 12.2 | 36.7-54.8 |
| | | Positive | 243 | 45.7 | **46.98** | 12.5 | 35.5-55.9 |
| IgA | Female | Negative | 54 | 214.3 | **200.00** | 97.0 | 157-250 |
| | | Positive | 3 | 235.3 | **274.00** | 105.5 | 116-316 |
| | Male | Negative | 140 | 245.6 | **233.50** | 101.9 | 176.5-302.5 |
| | | Positive | 2 | 208.0 | **208.00** | 104.7 | 134-282 |
| IgG | Female | Negative | 54 | 1076.4 | **1062.50** | 191.3 | 964-1186 |
| | | Positive | 3 | 1082.7 | **1095.00** | 152.9 | 924-1229 |
| | Male | Negative | 140 | 1061.2 | **1029.00** | 227.2 | 903-1181.5 |
| | | Positive | 2 | 1185.5 | **1185.50** | 436.3 | 877-1494 |
| IgM | Female | Negative | 54 | 143.1 | **129.50** | 64.6 | 94-169 |
| | | Positive | 3 | 114.3 | **89.00** | 53.7 | 78-176 |
| | Male | Negative | 140 | 101.8 | **90.00** | 61.3 | 64.5-121 |
| | | Positive | 2 | 86.0 | **86.00** | 15.6 | 75-97 |
| MCV | Female | Negative | 3618 | 91.2 | **91.50** | 4.8 | 88.4-94.4 |
| | | Positive | 142 | 91.2 | **91.40** | 4.1 | 88.9-93.5 |
| | Male | Negative | 6141 | 90.9 | **91.00** | 4.6 | 88.1-93.8 |

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | Positive | 204 | 90.6 | **91.00** | 4.8 | 88-94.1 |
| WBC | Female* | Negative | 4270 | 7.8 | **7.67** | 1.9 | 6.48-8.96 |
| | | Positive | 157 | 7.5 | **7.25** | 1.5 | 6.28-8.57 |
| | Male | Negative | 6949 | 7.2 | **7.02** | 1.8 | 5.99-8.2 |
| | | Positive | 229 | 7.1 | **6.98** | 1.6 | 6.01-8.03 |
| Hb | Female | Negative | 4269 | 13.8 | **13.80** | 0.9 | 13.2-14.4 |
| | | Positive | 157 | 13.7 | **13.80** | 0.9 | 13.2-14.3 |
| | Male* | Negative | 6949 | 15.5 | **15.50** | 1.0 | 14.9-16.2 |
| | | Positive | 229 | 15.3 | **15.30** | 1.0 | 14.7-15.8 |
| HCT | Female | Negative | 4269 | 42.4 | **42.30** | 2.7 | 40.6-44 |
| | | Positive | 157 | 42.1 | **42.00** | 2.5 | 40.5-43.6 |
| | Male* | Negative | 6949 | 46.8 | **46.80** | 2.8 | 45-48.6 |
| | | Positive | 229 | 46.2 | **45.90** | 3.0 | 44.3-47.7 |
| PLT | Female | Negative | 4268 | 265.9 | **261.00** | 56.6 | 228-300 |
| | (t) | Positive | 157 | 261.0 | **255.00** | 60.5 | 219-296 |
| | Male | Negative | 6949 | 236.8 | **233.00** | 49.6 | 204-266 |
| | | Positive | 229 | 237.9 | **234.00** | 50.2 | 203-266 |
| Neutrophil count | Female* | Negative | 4268 | 4.7 | **4.53** | 1.4 | 3.65-5.47 |
| | | Positive | 157 | 4.4 | **4.27** | 1.2 | 3.56-5.08 |
| | Male | Negative | 6949 | 4.3 | **4.10** | 1.4 | 3.34-4.95 |
| | | Positive | 229 | 4.2 | **4.10** | 1.2 | 3.24-4.97 |
| Neutrophil % | Female | Negative | 4268 | 59.2 | **59.40** | 7.4 | 54.2-64.3 |
| | | Positive | 157 | 58.1 | **58.10** | 7.2 | 54-62.9 |
| | Male | Negative | 6949 | 58.6 | **58.70** | 7.5 | 53.6-63.6 |
| | | Positive | 229 | 58.8 | **58.70** | 7.0 | 54.6-63.5 |
| Lymphocyte count | Female* | Negative | 4267 | 2.5 | **2.39** | 0.7 | 1.97-2.88 |
| | | Positive | 157 | 2.4 | **2.35** | 0.6 | 2.02-2.81 |
| | Male | Negative | 6949 | 2.2 | **2.18** | 0.6 | 1.8-2.62 |
| | | Positive | 229 | 2.2 | **2.17** | 0.6 | 1.8-2.51 |
| Lymphocyte % | Female | Negative | 4267 | 32.0 | **31.70** | 6.9 | 27.4-36.5 |
| | (t) | Positive | 157 | 33.0 | **33.10** | 7.0 | 28.4-37 |
| | Male | Negative | 6949 | 31.5 | **31.30** | 6.9 | 26.8-36.1 |
| | | Positive | 229 | 31.4 | **31.70** | 6.3 | 26.7-35.6 |
| Monocyte count | Female | Negative | 4267 | 0.5 | **0.46** | 0.1 | 0.37-0.55 |
| | (t) | Positive | 157 | 0.5 | **0.44** | 0.1 | 0.36-0.52 |
| | Male | Negative | 6949 | 0.5 | **0.46** | 0.1 | 0.38-0.56 |
| | | Positive | 229 | 0.5 | **0.47** | 0.1 | 0.38-0.55 |
| Monocyte % | Female | Negative | 4267 | 6.1 | **6.00** | 1.4 | 5.1-6.9 |
| | | Positive | 157 | 6.1 | **6.00** | 1.4 | 5.2-6.9 |
| | Male | Negative | 6949 | 6.7 | **6.60** | 1.5 | 5.7-7.6 |
| | | Positive | 229 | 6.7 | **6.70** | 1.4 | 5.8-7.6 |
| Eosinophil | Female | Negative | 4268 | 0.2 | **0.14** | 0.1 | 0.09-0.21 |

medRxiv preprint doi: https://doi.org/10.1101/2021.04.28.21256242; this version posted May 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| count | | | | | | | |
| | | Positive | 157 | 0.2 | **0.13** | 0.1 | 0.09-0.19 |
| | Male | Negative | 6949 | 0.2 | **0.16** | 0.1 | 0.1-0.24 |
| | | Positive | 229 | 0.2 | **0.15** | 0.1 | 0.09-0.23 |
| Eosinophil % | Female | Negative | 4268 | 2.2 | **1.80** | 1.6 | 1.2-2.8 |
| | | Positive | 157 | 2.3 | **1.80** | 1.7 | 1.1-2.8 |
| | Male | Negative | 6949 | 2.7 | **2.20** | 1.8 | 1.4-3.4 |
| | | Positive | 229 | 2.5 | **2.10** | 1.7 | 1.4-3.2 |
| Basophil count | Female | Negative | 4268 | 0.0 | **0.03** | 0.0 | 0.02-0.05 |
| | | Positive | 157 | 0.0 | **0.04** | 0.0 | 0.02-0.05 |
| | Male | Negative | 6949 | 0.0 | **0.03** | 0.0 | 0.02-0.04 |
| | | Positive | 229 | 0.0 | **0.03** | 0.0 | 0.02-0.04 |
| Basophil % | Female | Negative | 4268 | 0.5 | **0.40** | 0.2 | 0.3-0.6 |
| | (t) | Positive | 157 | 0.5 | **0.50** | 0.3 | 0.3-0.6 |
| | Male | Negative | 6949 | 0.5 | **0.50** | 0.2 | 0.3-0.6 |
| | | Positive | 229 | 0.5 | **0.50** | 0.2 | 0.4-0.6 |

*p<0.001

(t)p<0.2

Supplementary Table II. Descriptive analysis of age, immunoglobulins (mg/dL), Hb(g/dL), MCV, hemogram counts (cells*10^3/µL) and percents, of reactive and non-reactive donations by sex

## Figures

Figure 1. COVID-19 seropositive donation rate 2020 evolution by weeks. Temporal series' model (mobile median t=6; exponential smoothing model $R^2$=0.991;p<0.001)


% positive donations
8,00
6,00
4,00
2,00
,00
0,1 0,1 0,1 0,1 0,1 0,1 0,1 0,2 0,4 1,0 2,0 3,7 5,6 7,2 7,8 7,7 7,1 6,5 6,3 6,5 6,9 7,2 7,4 7,4 7,2 6,7 6,4 6,4 6,4 6,4 6,4
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
Week